No abstract

No abstract

Background: Hypertensive patients undergoing antihypertensive therapy are more prone to insulin resistance (IR). Thus, it is essential to monitor its prevalence, metabolic consequences and to individualize antihypertensive therapy to negate its potential adverse effects. Therefore, the presented study assessed the prevalence of IR among hypertensive patients undergoing antihypertensive therapy. Methodology: This prospective study involved 200 patients of either sex, diagnosed with essential hypertension, and undergoing treatment. Data regarding age, gender, medical history, body mass index (BMI), and waist circumference were collected. Laboratory   investigations   for   fasting    blood    sugar    levels, serum    fasting    Insulin    levels, lipid    profile, and    glycosylated    hemoglobin    were performed. Homeostatic model assessment of IR (HOMA IR) was calculated. Statistical analysis was performed by using R software (Version. 3.6.0). Results: The prevalence of IR in hypertensive nondiabetic patients was 39%. The mean age and BMI of patients were 58.70 ± 16.64 year and 23.10 ± 2.57 kg/m2, respectively. The mean fasting blood sugar levels were 108.24 ± 20.99 mg/ dl. The mean HOMA IR levels were >2.8. IR was more in users of beta?blockers than in angiotensin?converting enzyme (ACE) inhibitors and   calcium   channel   blockers, as   a   significant   association   was   observed   between   the   class   of   hypertensive   drugs   and   presence   of       IR (P < 0.05).  A significant association (P < 0.05) was observed between the duration of hypertension and IR indicated by HOMA IR >2.5 in patients on beta?blockers and on ACE inhibitors. Conclusion: Antihypertensive drugs like beta?blockers decrease insulin sensitivity in hypertensive patients leading to increased prevalence of IR.

No abstract

No abstract